Introduction {#Sec1}
============

The steady increase in interest and availability of focal articular cartilage repair techniques and the good long-term results achieved during the last decade have increased the heterogeneity of the patients requiring cartilage repair \[[@CR5], [@CR8], [@CR39], [@CR40]\]. That is, inclusion criteria for cartilage repair now range from single defects in young and active patients to early arthritic lesions in older (active) patients.

Although the focus on patient profiling has increased in recent years, treatment selection is still largely based on the preference of the surgeon and availability of different treatment types. Most surgeons agree that microfracture (MF) is a good option for smaller defects, while autologous chondrocyte implantation (ACI) is preferred for larger lesions \[[@CR3]\]. The clinical outcome seems dependent on the patient's age, level of activity, defect location and treatment delay \[[@CR3], [@CR12], [@CR19], [@CR25], [@CR43]\]. It is important to note that these findings are based on studies that have excluded certain patients, despite them being suitable for articular cartilage repair procedures, as most (randomized) trials have strict inclusion criteria such as a maximum age or number of defects \[[@CR1], [@CR18], [@CR21], [@CR44], [@CR48], [@CR49]\]. Only a handful of studies include salvage procedures for (young) patients with early osteoarthritic lesions \[[@CR29]\]. Moreover, it has been shown that the methodological quality of studies in cartilage repair is generally low \[[@CR20]\]. As such, there is a need for an evidence based selection procedure to identify patients suitable for focal cartilage repair.

The purpose of this prospective study was to analyze the clinical outcome of patients following the application of extensive profiling strategies, by an experienced cartilage surgeon (MB), to a heterogenic group of patients suitable for cartilage repair to provide evidence based tools for treatment selection in a clinical environment.

Materials and Methods {#Sec2}
=====================

Between 2006 and 2008, two hundred and sixteen patients suitable for focal cartilage repair were followed in this prospective study. The inclusion criteria for the study were: traumatic or degenerative symptomatic full thickness grade III to IV International Cartilage Repair Society lesions (ICRS) \[[@CR9], [@CR35]\] on the femur, trochlea and patella. The most important indicators for treatment were pain in rest and motion and (occasional) locking of the joint. In addition, a baseline Brittberg-Peterson VAS ≥ 50 contributed strongly to the decision for surgery. Patients were excluded from the study if they had multiple defects in one knee that were treated with different techniques, e.g. MF and ACI and/or opening wedge osteotomy, symptomatic cartilage or ligament injuries in both knees, widespread osteoarthritis, inflammatory arhtritis and/or incomplete baseline questionnaires (\>3 missing items per questionnaire). During the initial screening, several patient characteristics such as age, BMI, smoking, defect size, defect location, defect cause, symptom to treatment delay and previous procedures, as well as baseline outcome were recorded in a database. All patients gave their informed consent prior to inclusion in this study. A senior surgeon (MB) in a specialized cartilage repair centre treated all patients.

Treatment strategy and surgical techniques {#Sec3}
------------------------------------------

For the first and second line (subsequent to previous repair) treatment of smaller defects (≤2.5 cm^2^), MF as described by Steadman was used \[[@CR47]\]. Hyalograft C autografts \[[@CR38]\] were used for the first and second line treatment of larger defects (\>2.5 cm^2^) while carbon-fiber scaffold implantation was used as a salvage procedure for medium to large (≥1.5 cm^2^) early osteoarthritic (ICRS grade III--IV) defects. In addition, MF and carbon-fiber scaffolds were used for partial graft repair (i.e. repair of a failure of up to one-third of a previous created autologous chondrocyte graft). The Hyalograft C technique was preferred over MF for patients with high (sport related) physical demands with lesions 1.5--2 cm^2^ as well as patients with more than two previous cartilage repair procedures. Figure [1](#Fig1){ref-type="fig"} provides an overview of the predefined treatment algorithm used in this study.Fig. 1Treatment algorithm with pain, lesion type, defect size and patient activity as indicators for treatment selection. \*International Cartilage Repair Society

After drilling down to the vascular subchondral bone, woven carbon-fiber scaffolds were implanted as rods for convex surfaces and pads for concave surfaces \[[@CR4], [@CR7], [@CR27], [@CR33]\]. A Hyalograft C implantation for all femoral and trochlear defects was performed with arthroscopy, whereas mini-arthrotomy was used for patellar lesions. A treatment was considered a failure if during a second look arthroscopy, a patient needed a new repair procedure for at least two-thirds of the cartilage defect.

Rehabilitation {#Sec4}
--------------

All patients were weight bearing immediately after surgery, walking with crutches for 4- to 6-weeks to the extent allowed by an individual's pain tolerance. Patients with larger defects (\>2 cm^2^) and all patients treated with Hyalograft C received an additional knee brace that was locked in extension for 2-weeks and unlocked for 4-weeks. Each patient trained once to twice daily under supervision of a specialized physiotherapist for 6-weeks and self-training exercises were recommended for further 6-weeks. Return to full activity was not permitted until at least 6-months post-operatively, depending on an individual's clinical improvement.

Outcome measurement {#Sec5}
-------------------

Patients were asked to complete four patient-based questionnaires: the Knee Injury and Osteoarthritis Outcome Score (KOOS), the Brittberg-Peterson Visual Analogue Scale (VAS), the Lysholm Knee Scoring Scale and a subjective evaluation of clinical improvement (SECI) prior to and 3 years after surgery. The KOOS was designed for the follow-up of knee injury and osteoarthritis and has been validated for the treatment of cartilage lesions \[[@CR2], [@CR3], [@CR41]\]. A modified version of the Lysholm scale has been validated to assess cartilage damage \[[@CR45]\]. The Brittberg-Peterson VAS contains 13 items to measure different parameters of pain and function, on a scale of 0--100, where a score of 100 indicates the worst outcome \[[@CR39]\]. The SECI consisted of a question regarding post-operative improvement (completely improved/much better/slightly improved/unchanged or worse) \[[@CR6]\].

Statistical analysis {#Sec6}
--------------------

Paired 2-tailed *t* tests were used to measure the improvement from baseline scores for each treatment type. Unpaired 2-tailed *t* tests were used to compare the clinical outcomes between different treatment types.

For each separate treatment, as well as for all procedures, multiple linear regression analysis with backward elimination was used to determine prognostic factors that influenced the clinical outcome. To identify what influence the location of the defect had, the medial femoral condyle and patella were compared to all other sites. The defect cause was included in the analysis as either traumatic or non-traumatic. To ensure valid inclusion in the regression model, each patient's characteristics were subjected to a normality test using the Kolmogorov--Smirnov coefficient, a test for inter-variable correlation with the Pearson correlation coefficient and the variance inflation factor (VIF) and a test for autocorrelation with the Durbin-Watson coefficient. A VIF close to zero is considered indicative for multicollinearity \[[@CR10]\]. A Durbin-Watson coefficient close to zero or four suggests strong negative and strong positive autocorrelation respectively \[[@CR13]\]. Characteristics that were not normally distributed were excluded from the regression analysis. To exclude a possible treatment-by-covariate effect between the treatment types and the patient characteristics, a Levene homogeneity test was used. For each characteristic, the regression coefficient (*B*) along with the *P* value and 95% confidence interval (CI) was obtained. The *B* coefficient indicated the change in clinical outcome score for the presence or alteration of an included variable. Multiple logistic regression analysis was used to identify risk factors for failure after treatment and determine their separate odds ratios, along with the *P* values and 95% CI's \[[@CR11]\]. Statistical analysis was performed with SPSS 17.0. *P* values \< 0.05 were considered statistically significant.

Results {#Sec7}
=======

Of the 216 patients, 86 patients were treated with MF, 71 with Hyalograft C and 59 with carbon-fiber scaffolds. For MF, 10 patients had incomplete baseline questionnaires and 11 patients were lost to follow-up. For Hyalograft C, 17 patients were excluded (incomplete: *n* = 6, lost to follow-up: *n* = 11). For carbon-fiber scaffolds, 12 patients were excluded (incomplete: *n* = 2, lost to follow-up: *n* = 10). From the resulting 166 patients, three separate cohorts were obtained: 65 patients were treated with MF; 54 with Hyalograft C and 47 with carbon-fiber scaffolds. Table [1](#Tab1){ref-type="table"} summarizes the demographics and baseline characteristics.Table 1Demographics and baseline characteristicsCharacteristicMicrofracture (*n* = 65)Hyalograft C (*n* = 54)Carbon fiber (*n* = 47)Age (mean years ± SD)40 ± 1237 ± 947 ± 9Men54%63%62%BMI (mean ± SD)26.2 ± 4.325.3 ± 3.626.5 ± 5.5Smoking (*n*)1057Multiple defects (*n*)162516Defect size (mean cm^2^ ± SD)1.8 ± 1.53.9 ± 2.32.7 ± 1.9Location: medial (*n*)281327Lateral (*n*)1023Trochlea (*n*)862Patella (*n*)3101Femur and trochlea (*n*)121412Femur and patella (*n*)331Trochlea and patella (*n*)161Sports-related injury65%52%68%Treatment delay (months ± SD)97 ± 10079 ± 62100 ± 85Second line treatment35%41%72%Diagnostic arthroscopy (*n*)422313Previous treatment microfracture (*n*)12137Previous treatment carbon fibers (*n*)5319Previous treatment ACI (*n*)668Prior ACL reconstruction (*n*)7116Time from ACL reconstruction^a^ (months)66 ± 8951 ± 48144 ± 36Baseline VAS (mean ± SD)51.9 ± 19.456.1 ± 19.755.5 ± 18.1Baseline overall KOOS (mean ± SD)47.8 ± 15.446.3 ± 17.645.2 ± 17.2Baseline Lysholm^b^52.5 ± 18.251.6 ± 21.844.3 ± 18.6Partial menisectomy (*n*)201018Total menisectomy (*n*)572Partial (1/3) graft repair (*n*)10018Opening wedge osteotomy (*n*)557Follow up (months ± SD)34.0 ± 530.0 ± 832.0 ± 6Failures (*n*)887Time to treatment failure (months ± SD)17.0 ± 6.810.6 ± 4.717.1 ± 4.8*ACL* anterior cruciate ligament, *VAS* Brittberg Petersson visual analogue scale, *KOOS* knee injury and osteoarthritis outcome score^a^Time between ACL reconstruction and cartilage repair^b^Tegner Lysholm Knee Scoring Scale

Clinical assessment {#Sec8}
-------------------

The average follow-up time for MF, Hyalograft C and carbon-fiber scaffolds was 38 ± 5 months, 36 ± 8 months and 36 ± 6 months, respectively. The baseline scores were comparable for MF and Hyalograft C (n.s.) and slightly (0--4 points) lower for carbon-fiber scaffolds (−8 points in the Lysholm score (*P* = 0.003). (Table [1](#Tab1){ref-type="table"}) Statistically significant pre- to post-operative improvement was seen for all scores of the MF and Hyalograft C groups. (*P* \< 0.001) For carbon-fiber-scaffolds the clinical improvement was good. (*P* \< 0.001--0.002) The improvement from baseline was higher for both the MF and Hyalograft C cohorts, compared to carbon-fiber scaffolds and statistically significant for the KOOS sports and QoL subscales. (*P* \< 0.05) The clinical improvement for all scores and subscales is shown in Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. The SECI score was good with slight to complete improvement reported in 82% of MF procedures, 88% of Hyalograft C implantation and 80% for carbon-fiber procedures respectively. For all procedures, patients with anterior cruciate ligament (ACL) reconstruction improved on the KOOS and VAS (*P* \< 0.05) but did not show a significant improvement in their Lysholm score (n.s.).Table 2Mean improvement from baseline in the Knee Injury and Osteoarthritis Outcome Score (KOOS), Brittberg-Peterson Visual Analogue Scale (VAS) and Lysholm Knee Scoring Scale 3 years after surgeryOutcome scoresMicrofractureHyalograft CCarbon fiberScore ± SD*P* valueScore ± SD*P* valueScore ± SD*P* valueVAS19 ± 33\< 0.00125 ± 26\< 0.00117 ± 18\< 0.001KOOSSymptoms20 ± 21\< 0.00117 ± 23\< 0.00112 ± 240.003KOOSPain23 ± 23\< 0.00123 ± 26\< 0.00112 ± 210.001KOOSADL19 ± 20\< 0.00119 ± 23\< 0.00110 ± 200.004KOOSSports22 ± 29\< 0.00118 ± 26\< 0.0019 ± 31n.s.KOOSQoL22 ± 24\< 0.00123 ± 25\< 0.00113 ± 230.001KOOSTotal21 ± 20\< 0.00120 ± 21\< 0.00111 ± 200.002Lysholm15 ± 22\< 0.00118 ± 24\< 0.00113 ± 18\< 0.001*SD* standard deviationFig. 2Mean improvement from baseline and 95% Confidence intervals for the knee injury and osteoarthritis outcome Score (KOOS), the Brittberg-Peterson visual analogue scale (VAS) and the Lysholm Knee Scoring Scale 3 years after surgery

Linear regression analysis {#Sec9}
--------------------------

Of the patient characteristics, smoking and treatment delay had to be excluded from analysis due to failed normality tests (n.s.). For the remaining variables, no multicollinearity or autocorrelation was observed in any of the treatment types (VIF 1.000--1.127, Durbin Watson 1.997--2.232). The Levene tests of homogeneity of regression slopes were not statistically significant (n.s.) indicating no treatment by covariate interaction.

Patient age, BMI, defect cause and defect size did not seem to influence clinical outcome (n.s.). Patellar and medial lesions did not significantly differ in outcome scores compared to other defect locations for any of the treatment groups (n.s.).

In the MF cohort, patients with partial (1/3) graft repairs scored 24--32 points less improvement from baseline (regression coefficient (*B*) −24.0 to −32.4) on KOOS Pain, Sports and QoL subdomains (*P* \< 0.05), while partial graft repairs did not reduce clinical outcome in the carbon-fiber group (n.s.).

For Hyalograft C, patients with prior ACL reconstruction had reduced improvement from baseline compared to patients without prior ACL reconstruction. (VAS *B* −20.6, overall KOOS *B* −13.4, Lysholm *B* −19.8, *P* = 0.006--0.042). In all patients, single defects scored 13.0, 8.4 and 8.1 points higher on KOOS Sports and QoL and Lysholm scale respectively when compared to multiple defects (*P* \< 0.05).

Failures {#Sec10}
--------

In both the MF and Hyalograft C cohort there were 8 failures while there were 7 failures in the carbon-fiber group. (Table [1](#Tab1){ref-type="table"}) Of all failures 91% occurred within 2-years and 35% within 1-year. Patients with prior cartilage repair treated with MF were more likely to fail (Odds Ratio 20.5, 95% confidence interval 3.4--33.2, *P* = 0.003).

Discussion {#Sec11}
==========

The most important finding of the present study was that excellent clinical outcome was obtained using the patient profiling strategies of one experienced cartilage surgeon (MB) in a heterogenic population with chondral/osteochondral as well as early osteoarhtritic lesions. As such, it supports the use of the predefined treatment algorithm in a clinical environment (Fig. [1](#Fig1){ref-type="fig"}).

Although Hyalograft C was generally used for larger lesions, highly statistically significant clinical improvement after 3-years was achieved for both the MF and Hyalograft C cohorts. (Table [2](#Tab2){ref-type="table"}) This high clinical improvement is similar to 3-year results from randomized and non-randomized studies of patients treated with cartilage repair \[[@CR21], [@CR26], [@CR31], [@CR43]\]. As pain relief was considered one of the primary goals of treatment, the statistically significant improvement (*P* \< 0.001) on the VAS and KOOS pain subscale for each separate group (Table [2](#Tab2){ref-type="table"}) further underlines the effectiveness of the current profiling strategies.

Even though Hyalograft C was used more often in active patients, the improvement of the KOOS sports subscale was comparable with MF after 3 years. However, long-term results might be more indicative for these patients as Hyalograft C has been found to have similar clinical and sports related outcome compared to MF after 2-years while achieving a superior clinical (sport related) outcome after 5-years \[[@CR23]\]. The higher histomorphometric and histologic scores previously demonstrated in ACI compared to MF, in addition to a higher and more durable return to sports found in athletes, further support our treatment algorithm, in which Hyalograft C is preferred for more active patients \[[@CR30], [@CR44]\].

In a prospective case series, Filardo et al. \[[@CR15]\] found second-generation ACI to achieve a lower clinical improvement if patients underwent previous surgeries such as menisectomy, ACL reconstruction, MF or mosaicplasty. This was corroborated in our Hyalograft C cohort, where patients with a prior ACL reconstruction exhibited a significantly lower clinical improvement from baseline. One explanation could be a disturbed joint homeostasis, that is to say that remaining instability and/or inflammation may disturb cartilage regeneration \[[@CR42]\]. Moreover, the previously illustrated increased odds ratio of cartilage degradation after ACL rupture might continue even after reconstruction \[[@CR17]\]. This emphasises the need for further research aiming at improving clinical outcome of patients with ACL ruptures and (subsequent) cartilage damage. Similarly to Filardo, Minas et al. \[[@CR28]\] showed an increased failure rate of first generation ACI after marrow stimulating techniques. Although we did find a higher failure rate for MF as second line treatment, this did not occur in the Hyalograft C and carbon-fiber group. In the above-mentioned reports, a predefined treatment algorithm could not be identified. In addition, Filardo et al. \[[@CR30]\] applied cartilage repair by surgeons in different centres. Therefore, careful patient selection and treatment by one senior surgeon following a predefined treatment algorithm, may improve treatment results. This approach could explain the superior clinical outcome we achieved for patients receiving second line cartilage repair.

In the current study, carbon-fiber scaffold implantation resulted in overall lower clinical improvement than the other two cohorts. However, carbon-fiber scaffolfds were used for a separate cohort with early osteoarthritic lesions and demonstrated a high statistically significant improvement in the VAS, KOOS Pain and Lysholm score (*P* \< 0.001). Surprisingly, Nehrer et al. \[[@CR32]\] did not find a significant improvement in Lysholm for a similar salvage group with Hyalograft C after 3-years. Taking the above into account, this study demonstrates that carbon-fibers are useful for salvage repair and supports the treatment of this patient category.

MF and carbon-fiber implantation were also used for partial graft repair. As MF resulted in a significantly reduced clinical improvement in these patients, carbon-fibers seem to be a better option for this group as well. Nevertheless, further studies are needed to correctly identify risk factors for partial failures and improve the clinical outcome, as evidence for treatment of this challenging group is lacking in current literature.

With regard to the patient characteristics, patient age did not influence clinical outcome. This finding might be attributable to the careful treatment selection of the surgeon (MB) as older patients are more likely to have early osteoarthritic lesions and receive carbon-fiber implants. However, as no affect of age was found after correcting for treatment type, the previously illustrated influence of this variable should be considered together with other characteristics such as (sports) activity and overall health as well \[[@CR12], [@CR18], [@CR21], [@CR24], [@CR25], [@CR34]\]. Moreover, our findings are similar to a 2-year follow-up study showing no difference in clinical outcome after ACI for patients 40 years and older compared to younger patients \[[@CR34]\]. In addition, good clinical results have recently been demonstrated after 2- to 5-years in patients 40 years and older after second-generation ACI \[[@CR22]\].

In recent years, medial as well as lateral lesions have been shown to have better clinical outcome while patellar lesions have been reported to be more challenging to repair, possibly due to greater biomechanical shearing forces \[[@CR12], [@CR25], [@CR36], [@CR37]\]. However, when comparing medial and patellar lesions to other sites, we found no statistically significant difference in outcome scores. This is in accordance with a previous study demonstrating similar statistically significant (*P* \< 0.001) improvement in clinical outcome after treatment of patellofemoral lesions (mean size 4.7 cm^2^) treated with Hyalograft C \[[@CR16]\].

Regardless of treatment type, multiple defects resulted in lower clinical improvement compared to single defects. Similarly, Solheim et al. \[[@CR46]\] found inferior clinical outcome for MF of multiple versus single defects. Although these patients seem to benefit of cartilage repair as shown by improved outcome scores, multiple defects should be regarded as a separate, more difficult patient population.

Limitations of this study could be that it lacks randomization, includes different locations in the knee with a variety of defect etiologies and did not include a control group. However, we stress that the primary goal of this observational prospective study was not to demonstrate superiority of one particular treatment but to evaluate the clinical outcome of a heterogenic patient population after treatment of one experienced surgeon (MB) according to a predefined selection algorithm. Moreover, the indications of the cartilage repair procedures do not overlap, which may emphasize why randomization in this patient category is difficult and why previous randomized trials do not include all patients suitable for cartilage repair \[[@CR14], [@CR20]\]. The strengths of this study lie in the treatment of a relatively large group of patients and the inclusion of a wide range of patients suitable for cartilage repair in different cohorts. Unlike most cartilage repair reports, where data are published based on multi-surgeon and/or centre studies, this study focused on a single senior surgeon in one specialized cartilage repair centre.

Conclusion {#Sec12}
==========

To the best of our knowledge, this is the first assessment of the treatment strategies used by one experienced cartilage surgeon based on lesion and patient characteristics. We provide a treatment algorithm with pain, lesion type, defect size and patient activity as indicators for treatment selection (Fig. [1](#Fig1){ref-type="fig"}). Our data suggest Hyalograft C to be a good second line treatment option and support the treatment of early osteoarthritic lesions. The treatment algorithm and new insights of this single-surgeon study could be used for patient profiling in a day-to-day clinical environment.
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